Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Mimedx (MDXG) over the last 15 years, with Q4 2024 value amounting to $7.4 million.

  • Mimedx's Net Income towards Common Stockholders fell 8340.81% to $7.4 million in Q4 2024 from the same period last year, while for Sep 2025 it was $7.4 million, marking a year-over-year decrease of 9063.09%. This contributed to the annual value of $42.0 million for FY2024, which is 2472.94% down from last year.
  • Per Mimedx's latest filing, its Net Income towards Common Stockholders stood at $7.4 million for Q4 2024, which was down 8340.81% from $7.9 million recorded in Q3 2024.
  • In the past 5 years, Mimedx's Net Income towards Common Stockholders ranged from a high of $44.8 million in Q4 2023 and a low of -$52.0 million during Q3 2020
  • Moreover, its 5-year median value for Net Income towards Common Stockholders was -$3.5 million (2021), whereas its average is -$1.5 million.
  • In the last 5 years, Mimedx's Net Income towards Common Stockholders crashed by 51992.08% in 2020 and then surged by 68183.12% in 2022.
  • Quarter analysis of 5 years shows Mimedx's Net Income towards Common Stockholders stood at -$18.1 million in 2020, then soared by 92.26% to -$1.4 million in 2021, then surged by 681.83% to $8.1 million in 2022, then skyrocketed by 451.13% to $44.8 million in 2023, then plummeted by 83.41% to $7.4 million in 2024.
  • Its Net Income towards Common Stockholders was $7.4 million in Q4 2024, compared to $7.9 million in Q3 2024 and $17.6 million in Q2 2024.